Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Caplyta® (lumateperone) – New drug approval
December 23, 2019 - Intra-Cellular Therapies’ announced the FDA approval of Caplyta (lumateperone), an atypical antipsychotic indicated for the treatment of schizophrenia in adults.
